The use of autologous serum eye drops for the treatment of ocular surface disorders.

Abstract

OBJECTIVES:

To investigate the use of autologous serum (AS) eye drops in patients with ocular surface disorders who were refractory to conventional treatments.

METHODS:

A retrospective cohort study was conducted at a tertiary care centre. We included patients with a prescription of AS eye drops from December 2006 to January 2016. Electronic prescriptions (Prescriplant) and clinical histories were reviewed. A database with sociodemographic and pharmacotherapheutic variables was created. The efficacy was evaluated subjectively and adverse effects was a measurement of safety. AS eye drops were elaborated, in a laminar flow hood, with the blood samples for a final concentration of 20%.

RESULTS:

One hundred and seventy-three patients were considered for the study, 78.03% of them female. Their mean age was 63.87 years (SD 16.69). The use of AS eye drops was indicated for several diseases: corneal diseases (corneal ulcer or corneal persistent epithelial defects) (34.32%); Sjögren syndrome (17.16%); dry eye resulting from autoimmune disease (15.38%); and blepharitis/blepharospasm (12.43%). The regular dosage was every 3 or 4 hours (40.46%). 21.97% patients used the AS in one eye only. The mean length of treatment was 2.71 years. All patients, except one, improved their symptoms with the treatment and no one suffered harmful effects.

CONCLUSIONS:

Numerous national and international guidelines on dry eye treatment have been published, but they differ in dosing, concentration and indication of AS eye drops. Consequently, there is no consensus about the best therapy with AS. In this article we describe the clinical practice of AS eye drops. In the study, indications for AS therapy were mostly: corneal diseases; Sjögren syndrome; and dry eye resulting from autoimmune disease; and blepharitis or blepharospasm. Patients went to the hospital pharmacy to pick up AS eye drops before 90 days, it ensures the stability of eye drops. AS is an effective, safe and well tolerated treatment.

• Authors: Estela García-Martín, Sagrario Pernía-López, R M Romero Jiménez, Blanca García-Valcárcel, Pilar A Martínez-Ortega, María Sanjurjo-Saez
• Journal: European journal of hospital pharmacy : science and practice (Eur J Hosp Pharm) Vol. 26 Issue 6 Pg. 314-317 (Nov 2019) ISSN: 2047-9956 [Print] England
• PMID: 31798853 (Publication Type: Journal Article)
• Copyright: © European Association of Hospital Pharmacists 2019. No commercial re-use. See rights and permissions. Published by BMJ.